Physician profile
Jeremy Abraham Schreiber
NPI 1508234147
$1,719,303.92
in general payments reported to CMS, 2019-2025
26 companies · $478K in 2025
The $478K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211K · 2022: $329K · 2023: $423K · 2024: $279K · 2025: $478K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $825K · Travel and Lodging: $153K · Consulting Fee: $133K · Food and Beverage: $37K · Honoraria: $31K · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $825,091.50 |
| Travel and Lodging | $153,038.99 |
| Consulting Fee | $133,114.00 |
| Food and Beverage | $37,267.00 |
| Honoraria | $31,050.50 |
| Education | $122.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $475,123.54 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $283,527.17 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $264,519.52 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196,800.72 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $150,571.15 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $131,482.89 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $83,328.46 | 2024-2025 | Cobenfy |
| Biogen, INC. | $61,180.14 | 2022-2025 | Zurzuvae |
| Axsome Therapeutics, INC. | $53,189.73 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $9,729.90 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $7,962.87 | 2021-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $294.46 | 2022-2025 | Wegovy |
| Lundbeck LLC | $284.78 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $284.63 | 2024 | Qelbree |
| Sage Therapeutics, LLC | $274.77 | 2024-2025 | Zurzuvae |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $269.85 | 2021 | |
| Sunovion Pharmaceuticals INC. | $101.94 | 2021 | |
| Corium, LLC | $94.39 | 2023-2024 | Azstarys |
| Zealand Pharma US, INC. | $91.55 | 2022 | |
| Brainsway USA INC | $67.81 | 2024 | Brainsway Deep Tms System |
| Takeda Pharmaceuticals U.S.A., INC. | $28.00 | 2021 | |
| Noven Pharmaceuticals, INC. | $26.66 | 2022 | |
| Lilly USA, LLC | $23.50 | 2025 | Zepbound |
| Almatica Pharma LLC | $18.21 | 2023 | Loreev Xr |
| Eisai INC. | $14.16 | 2021 | |
| Alfasigma USA, INC. | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Schreiber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.